Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

They administered 5-aminolevulinic acid (5-ALA), a compound that blocks G4 formation, to model mice exhibiting Parkinson's-like symptoms. Impressively, 5-ALA treatment not only prevented α ...

By blocking G4 formation with 5-aminolevulinic acid, researchers prevented α-synuclein aggregation and motor symptoms in mice, presenting a potential new therapeutic strategy. G-quadruplexes act as ...